key: cord-0738954-r51zf1lg
authors: Khalili, Hamed; Zheng, Tenghao; Söderling, Jonas; Larsson, Emma; D'Amato, Mauro; Ludvigsson, Jonas F.
title: Association Between Collagenous and Lymphocytic Colitis and Risk of Severe COVID-19
date: 2021-02-19
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.02.029
sha: 2c815d783255d89ddd737ed6419091706e0fa05e
doc_id: 738954
cord_uid: r51zf1lg

nan

Microscopic colitis (MC) is a chronic inflammatory disease of the large intestine that presents with watery diarrhea and primarily affects older adults. We and others have demonstrated that MC is associated with an increased risk of death from infectious causes 1, 2 . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus first discovered in China, and responsible for Coronavirus Disease 2019 . To date, no study has evaluated the association between MC, its subtypes of collagenous colitis (CC) and lymphocytic colitis (LC) and COVID-19. We therefore sought to examine the risk of severe COVID-19 in patients with MC as compared to the general population. We also comapred the frequency of a risk variant from the 3p21.31 gene cluster associated with severe COVID-19 3 across MC subtypes.

We identified all patients with MC diagnosed from January 1 st , 1990 to December 31, 2016 through a nationwide pathology cohort, the Epidemiology Strengthened by histoPathology Reports in Sweden (ESPRESSO) (See Supplementary Material). We matched each patient with MC that was alive and living in Sweden as of February 1st, 2020 with up to 5 population comparators according to a propensity score with a max caliper width of 0.2 of the pooled standard deviation of the logit for each score. Propensity scores for likelihood of MC diagnosis were calculated from a list of demographics and comorbidities (See Supplementary Material). Data on demographics, comorbidities and medications were only available up to December 31, 2016 due to the Swedish government restrictions on updating non-COVID-19 related data in established cohorts during the time of pandemic.

Outcome ascertainment: Our primary outcomes were: (I) hospital admission with laboratory-confirmed COVID-19 as the primary diagnosis (ICD-10: U07.1), and (II) severe COVID-19, a composite outcome defined as: (a) COVID-19 intensive care admission, or (b) death due to COVID-19 or (c) any death within 30 days of hospital admission with COVID-19.

Follow-up time was calculated from February 1, 2020 until death, severe COVID-19, or July 31, 2020, whichever came first. We used Cox proportional hazard modeling conditioned on propensity score to estimate Hazard ratios (HRs) and 95% CI.

We included data from 359 individuals diagnosed with CC (average age 65.1 years; 85.2% females) and 172 patients with LC (average age 64.7 years; 78.5% females), whose genotypes were available for the analysis of the 3p21.31 locus. Patients had been previously recruited at tertiary gastroenterology clinics from three municipalities in Sweden (See Supplementary Material).

Genotyping and analysis of COVID-19 risk locus 3p21.31: J o u r n a l P r e -p r o o f The 3p21.31 locus was studied using MC patients' SNP rs13071258 genotypes, extracted from available Illumina Infinium Global Screening (GSA) array data. Association was tested by comparing rs13071258 allele frequencies in CC and LC cases, using adjusted logistic regression and inversevariance weighted fixed-effect meta-analysis (See Supplementary Material).

We identified 10 563 Individuals with a diagnosis of MC between 1990 and 2017 and propensityscore matched 10 552 (3 237 CC and 7 315 LC) of them to 52,624 population comparators. The baseline characteristics of participants with MC and population comparators are presented in Supplementary Table 1. In our primary analysis, we observed no increase in risk of hospital admission for COVID-19 or severe COVID in patients with MC ( Table 1) . There was however a significantly increased risk of hospital admission for COVID-19 (HR=3.40, 95%CI 2.03-5.70) and severe COVID-19 (HR=2.48; 95%CI 1.33-4.63) in patients with CC, compared to population comparators. There were no association between LC and risk of COVID-19 outcomes ( Table 1) . We also observed an increased risk of COVID-19 infections in patients with MC (HR = 1.27, 95% CI 1.08 -1.49) and CC (HR = 1.72, 1.29-2.28) but not LC (HR = 1.11, 95% CI, 0.91-1.36), as compared to population comparators. Additional adjustments for oral steroids (i.e. budesonide and prednisone) and PPI use, which were ascertained prior to December of 2016, yielded similar estimates for the association between CC and hospital admission (HR=3.20, 95% CI 1.46-6.99) and severe COVID-19 (HR=2.19, 95% CI 0.92-5.12). We explored the possibility that the observed association between CC and risk of COVID-19 outcomes may at least in part be related to genetic factors predisposing to severe COVID-19 3 . As shown in Supplementary Table 2 , rs13071258 A variant, which represents 3p21.31 risk locus for severe COVID-19, was significantly more common in CC compared to LC patients (respective allele frequencies 0.097 and 0.047; p = 0.00464 in the meta-analysis).

In a nationwide cohort in Sweden, we found no association between MC and severe COVID-19 infection after accounting for comorbidities. Interestingly, compared to population comparators, the CC subtype was associated with a significant increase in risk of severe COVID-19 infection. In line with this observation, increased prevalence of a known severe COVID-19 risk variant was detected in patients with CC compared to LC in a pilot genetic study.

Although the exact biologic mechanism behind the observed association between CC and severe COVID-19 outcomes is unknown, it is possible that the increased risk may in part be related to genetic factors that modify immune response to viral pathogens. This is supported by previous genetic findings that showed an increased risk of CC (but not LC) with an extended HLA haplotype (8.1) encoding several molecules with a critical role in immune response to microbial and viral pathogens [4] [5] [6] The strengths of our study include nationwide coverage of both MC cases and COVID-19 hospitalizations, large sample size, and availability of genetic data in 3 independent cohorts. The limitations of our study include lack of data on individual lifestyle factors and medications and comorbidities around the time of COVID-19 diagnosis, which may have resulted in misclassification of a number of confounders.

In this population-based cohort study, we found that CC but not LC is associated with an increased risk of severe COVID-19 infections. Additional studies are needed to corroborate our findings; if replicated, they may suggest the existence of specific pathogenetic mechanisms shared between COVID-19 infection and or severity and CC. 

The Epidemiology Strengthened by histoPathology Reports in Sweden (ESPRESSO) study contains biopsy data from Sweden's 28 pathology departments between 1965 and April 2017 (2.1 million unique individuals with a GI biopsy report) 1 . We identified patients with MC defined as having a colorectal biopsy (topography codes T67-68) with a SnoMed histopathology code of either M40600 or M47170. This method for ascertaining cases of MC has previously been validated and found to have a positive predictive value of 95% (95%CI=91-97%) 2 . Importantly, this method identified symptomatic cases with the most common reported symptoms were diarrhea (96% of patients), weight loss (24%) and abdominal pain (13%) 2 . This study was approved by the Stockholm Ethics Review Board (Number: 2014/1287-31/4, with a COVID-19 specific amendment: 2020-02307).

For the current study we retrieved data from the Swedish Patient Register (hospital-based inpatient and outpatient care) on the following comorbidities: cardiovascular disease including thromboembolic disease, diabetes mellitus, chronic obstructive pulmonary disease, end-stage renal disease, alcohol use disorders including alcohol-related liver disease, obesity / dyslipidemia, obstructive sleep apnea, cancer, and psychiatric disease. The Patient Register began in 1964 and became nationwide in 1987 3 . Most medical diagnoses in the register have a positive predictive value of 85-95% 3 . We also collected medications data from Swedish Prescribed Register. Medications included were steroids and use of proton pump inhibitors (PPIs), which were selected based on their associations with risk of MC and/or COVID-19 outcomes. Steroid use was defined as any use of oral prednisone or budesonide prior to matching date. Medication use was last updated on December 31, 2016. Propensity scores were derived from demographic data including age, sex, county, education and Nordic country of birth, which were ascertained on February 1, 2020 and medical comorbidities including cardiovascular disease, diabetes, COPD, end-stage renal disease, alcohol liver disease/alcohol use disorder, obesity/dyslipidemia, obstructive sleep apnea, cancer, and psychiatric disease, which were last updated on December 31, 2016.

Patients had been previously recruited at tertiary gastroenterology clinics from three municipalities in Sweden: Stockholm (Karolinska University Hospital, Sophiahemmet Hospital and Ersta Hospital), Malmo (Skåne University Hospital and Trelleborg Hospital) and Linköping (Linköping Hospital). The characteristics of most of these patients have previously been reported 4, 5 . Diagnosis of MC and its subtypes was made according to consensus criteria based on the presence of chronic non-bloody diarrhea and histological findings, including deposition of a subepithelial collagen layer of ≥10 μm and lymphocytic infiltration of the lamina propria, as previously described. Genetic analyses of Swedish MC patients are approved by the Stockholm Ethics Review Board (protocol 2016/271-31/1).

MC patients' genotypes were extracted for the locus 3p21.31 from available Illumina Infinium Global Screening (GSA) array genome-wide data, after standard quality control (excluding: population outliers via principal component analysis, related individuals, samples with phenotype-genotype discordant sex, call rate > 98%, heterozygosity rate > 3SD) and imputation (using the Haplotype Reference consortium panel and the EAGLE+PBWT pipeline) 6 . For the purpose of this study, we used genotype data available for the SNP marker rs13071258, which was imputed with high accuracy (INFO=0.898), and is a proxy in complete linkage disequilibrium (r 2 =1) with the rs11385942 marker giving rise to the strongest J o u r n a l P r e -p r o o f 1.03 (0.62-1.69) *Conditioned on propensity score which was derived from: age, sex, county, education, Nordic country of birth, and medical comorbidities updated last on December 31, 2016 (cardiovascular disease, diabetes, COPD, end-stage renal disease, alcohol liver disease/alcohol use disorder, obesity/dyslipidemia, obstructive sleep apnea, cancer, psychiatric disease).

Mortality of Patients With Microscopic Colitis in Sweden

All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Collagenous Colitis Is Associated with Hla Signature and Shares Genetic Risks with Other Immune-Mediated Diseases

Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis

HLA Associations Distinguish Collagenous From Lymphocytic Colitis

Human G protein-coupled receptor GPR-9

/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis

Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity

Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)

Validating microscopic colitis (MC) in Swedish pathology registers

External review and validation of the Swedish national inpatient register

Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis

HLA Associations Distinguish Collagenous From Lymphocytic Colitis

A reference panel of 64,976 haplotypes for genotype imputation

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Second-generation PLINK: rising to the challenge of larger and richer datasets

How to perform a meta-analysis with R: a practical tutorial

Nordic country of birth, and medical comorbidities including cardiovascular disease, diabetes, COPD, end-stage renal disease, alcohol liver disease/alcohol use disorder, obesity/dyslipidemia, obstructive sleep apnea, cancer, psychiatric disease were included in propensity score. ∆ Medication and comorbidities were last updated on

association signal in the original severe COVID-19 genome-wide association study (GWAS) 7 . 3p21.31 locus was tested by comparing rs13071258 allele frequencies in collagenous and lymphocytic colitis cases from the three municipalities, using logistic regression under an additive genetic model implemented in PLINK 2.0 (www.cog-genomics.org/plink/2.0/) 8 , adjusting for sex, age and top 10 principal components. Meta-analysis was performed, based on fixed-effect and the inverse-variance weighted approach using the R package "meta" 9 .Additional References: